Unaudited Financial Results along the limited review report from the Statutory Auditor of the Company for the quarter ended June 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech posted Q1 FY26 standalone revenue from operations of Rs 4,649.64 lakhs, up about 7.8% from Rs 4,311.46 lakhs in Q1 FY25. Total income rose to Rs 4,721.86 lakhs. Standalone profit after tax came in at Rs 616.08 lakhs versus Rs 569.96 lakhs, an 8.1% jump, with EPS at Rs 7.46 (vs Rs 6.90). Consolidated PAT was Rs 686.28 lakhs (including Rs 70.20 lakhs from associates Peptech Biosciences and Titan Media). Statutory auditor A N S K & Associates issued an unmodified (clean) limited review opinion on both standalone and consolidated results. The board also appointed Mr. Debendra Kumar Sabat as an Additional Independent Director, and re-appointed both Managing Directors (Mr. Naresh Kumar Singla and Mr. Suresh Chand Singla) for a fresh five-year term from April 1, 2026. The 33rd AGM is set for September 26, 2025, with a final dividend of Rs 2 per share and record date of September 19, 2025.
Steady mid-single-digit growth in revenue and profits with a clean audit opinion is a neutral-to-mildly-positive signal for shareholders; the Rs 2 final dividend and stable promoter-led management continuity add comfort, though growth is well below 20% thresholds so no strong earnings momentum trigger.